Search
Buclizine
go.drugbank.com/drugs/DB00354ApprovedIt was manufactured by Stuart Pharms and initially approved by the FDA in 1957. … [L6217] Following this, it was touted to be effective as an appetite stimulant in children when administered in the syrup form, however, this indication has not been validated.
Ansuvimab
go.drugbank.com/drugs/DB16385ApprovedHowever, to date, the most successful method appears to be the development of monoclonal antibodies (mAbs) against the GP<sub>1,2</sub> surface glycoprotein, as evidenced by the previously approved INMAZEB … [A207646] Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD.
Natalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigational[A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023. … In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008.
Levomenthol
go.drugbank.com/drugs/DB00825ApprovedInvestigationalMenthol mediates anesthetic properties and anti-irritating properties locally, thus it is widely used to relieve minor throat irritations.
Mixtures: Icy Hot Lidocaine No Mess Applicator Plus Menthol, NORAVER UProducts: AK47 Cooling Roll-On, Ion-TO Scalp Cleanser SAnthrax vaccine
go.drugbank.com/drugs/DB11003ApprovedInvestigational[L47561] There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023. … [L47526] It is considered one of the most likely agents to be used in a biological attack.
Sevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608] … Sevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain
Categories: MATE 2-K InhibitorsBrensocatib
go.drugbank.com/drugs/DB15638Approved[A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813] … Non-cystic fibrosis bronchiectasis (NCFB) is a chronic lung disease characterized by airway widening, mucus accumulation, and neutrophilic inflammation.
Synonyms: (S)-N-((S)-1-Cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo-(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamideIsoprenaline
go.drugbank.com/drugs/DB01064ApprovedInvestigational[A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline]. … Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion
Categories: Non-selective Beta-adrenergic AgonistsSynonyms: N-Isopropylnoradrenaline, N-IsopropylnorepinephrineFluocinolone acetonide
go.drugbank.com/drugs/DB00591ApprovedInvestigationalVet approved[T358] This type of device containing fluocinolone acetonide was developed by Taro Pharmaceuticals and approved by FDA in May 2016.[L4676]
Mixtures: Neo-Synalar, Neo-SynalarInternational brands: Co-FIuosinPiracetam
go.drugbank.com/drugs/DB09210ApprovedWithdrawnIn the UK, piracetam is prescribed mainly for myoclonus, but is used off-label for other conditions such as learning difficulties in children, memory loss or other cognitive defects in the elderly, and … It is not approved for any medical or dietary use by the FDA.